CRON vs. CGC, USNA, MNMD, BTMD, ACB, SRRK, ELVN, ABCL, PRTA, and BCRX
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Canopy Growth (CGC), USANA Health Sciences (USNA), Mind Medicine (MindMed) (MNMD), biote (BTMD), Aurora Cannabis (ACB), Scholar Rock (SRRK), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Prothena (PRTA), and BioCryst Pharmaceuticals (BCRX). These companies are all part of the "medical" sector.
Cronos Group (NASDAQ:CRON) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, community ranking, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.
In the previous week, Cronos Group had 9 more articles in the media than Canopy Growth. MarketBeat recorded 17 mentions for Cronos Group and 8 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.80 beat Cronos Group's score of 0.80 indicating that Canopy Growth is being referred to more favorably in the news media.
Cronos Group presently has a consensus target price of $3.00, suggesting a potential upside of 3.45%. Canopy Growth has a consensus target price of $4.87, suggesting a potential downside of 55.15%. Given Cronos Group's higher probable upside, analysts plainly believe Cronos Group is more favorable than Canopy Growth.
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 3.3% of Canopy Growth shares are held by institutional investors. 2.0% of Cronos Group shares are held by insiders. Comparatively, 0.4% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Cronos Group has higher earnings, but lower revenue than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Cronos Group received 444 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 19.80% of users gave Canopy Growth an outperform vote.
Cronos Group has a net margin of -61.31% compared to Canopy Growth's net margin of -326.75%. Cronos Group's return on equity of -3.06% beat Canopy Growth's return on equity.
Cronos Group has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
Summary
Cronos Group beats Canopy Growth on 13 of the 17 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
